Viz

Viz (also known as Viz.ai) helps physicians to identify anomalies in brain scans through machine learning. It uses deep learning algorithms to identify a suspected large vessel occlusion, a particularly disabling type of stroke, in a CT scan and alerts the stroke team specialist within minutes, reducing the time to treatment and increasing the chance of a better overall patient outcome.

Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about suspected stroke patients straight to a specialist who can intervene and treat. In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.

Viz's software is currently available in over 300 hospitals across the US.

In October 2019 Viz.ai raised a $50m Series B round led by Greenoaks, with participation from GV and Kleiner Perkins. The money will be used to expand Synchronised Care to more disease states and geographies.

Viz.ai is located in San Francisco and Tel Aviv.